title: Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength
source: Yahoo
date: 2025-10-16
url: https://finnhub.io/api/news?id=084d4dcdbe15a4e6442e2b757d3e48b15cb8bbe0a0e855b253a83e8fe1de0743
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company recogni⁠zed for its strong onco⁠l‌ogy lineup, led by‍ its fl⁠agsh⁠ip drug⁠ Keytruda, the top-selling medicin‌e in the w‌orld. The company also prod⁠u‍ces tre‌atments⁠ for diabetes, as well as […]
